论文部分内容阅读
目的检测IL-17在溃疡性结肠炎(ulcerative colitis,UC)患者血浆及结肠组织中的表达水平,探讨清肠化湿方联合美沙拉嗪协同增效的作用机制。方法选择24例轻、中度UC活动期湿热内蕴证患者,对其肠组织标本进行组织学分级,根据随机数字法分为联合组(12例)与西药组(12例),另选择12名体检健康者作为健康组,联合组予清肠化湿方联合美沙拉嗪治疗,西药组予美沙拉嗪口服,疗程3个月。治疗结束后,ELISA法检测血浆IL-17表达水平,免疫组化SP法检测肠黏膜组织中IL-17浸润。结果UC患者血浆及肠组织IL-17表达均高于健康组(P<0.05),且随组织学分级增加而升高。两组患者血浆及肠组织中IL-17表达较治疗前均降低(P<0.05),且联合组患者IL-17表达水平低于西药组(P<0.05)。结论清肠化湿方联合美沙拉嗪治疗可协同增效,通过下调UC患者体内IL-17的表达抑制肠道炎症。
Objective To detect the expression of IL-17 in the plasma and colon tissues of patients with ulcerative colitis (UC), and to explore the mechanism of the synergistic effect of purgation and dampness prescription combined with mesalazine. Methods Twenty-four patients with mild to moderate UC active damp-heat syndrome were enrolled in this study. Histological grading was performed on the intestinal tissue samples. According to the random number method, the patients were divided into the combined group (12 cases) and the western medicine group (12 cases) Healthy people as a group of health examination, the combined group to bowel Huashi Fang combined with mesalazine treatment, the Western medicine group to Mesalazine oral treatment for 3 months. After the treatment, the level of IL-17 in plasma was detected by ELISA, IL-17 in intestinal mucosa was detected by immunohistochemistry. Results The expression of IL-17 in plasma and intestinal tissue of patients with UC was higher than that of healthy group (P <0.05), and increased with the increase of histological grade. The expression of IL-17 in plasma and intestinal tissue in both groups was lower than that before treatment (P <0.05), and the level of IL-17 in combined group was lower than that in western medicine group (P <0.05). Conclusions Qingchang Huashi Decoction combined with mesalazine can be synergistic and inhibit intestinal inflammation by down-regulating the expression of IL-17 in UC patients.